SeekingAlpha · Nov 9, 2026
Arcutis Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-09. The following slide deck was published by Arcutis Biotherapeutics, Inc.
NASDAQ · ARQT
Healthcare · Biotechnology
$27.53
Up+$0.53 (+1.91%)
Updated Nov 13, 2026, 8:01 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · ARQT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
ARQT closed at $27.53 after 21 trading sessions, down 5.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $28.24 | $28.94 | $27.45 | $27.53 | 1.89M |
| Nov 11, 2026 | $27.50 | $28.65 | $27.20 | $28.38 | 2.49M |
| Nov 10, 2026 | $25.87 | $27.62 | $25.816 | $27.385 | 2.22M |
| Nov 9, 2026 | $25.65 | $26.43 | $25.23 | $26.20 | 2.76M |
| Nov 6, 2026 | $26.70 | $27.09 | $25.29 | $25.55 | 3.26M |
| Nov 5, 2026 | $29.00 | $29.49 | $25.78 | $27.00 | 7.6M |
| Nov 4, 2026 | $32.885 | $34.80 | $31.87 | $34.05 | 2.75M |
| Nov 3, 2026 | $31.32 | $32.39 | $31.265 | $32.00 | 1.62M |
| Nov 2, 2026 | $32.07 | $32.24 | $31.20 | $31.26 | 1.51M |
| Oct 30, 2026 | $32.335 | $32.69 | $31.67 | $32.07 | 1.88M |
| Oct 29, 2026 | $31.40 | $32.08 | $31.1471 | $31.97 | 1.75M |
| Oct 28, 2026 | $31.50 | $32.00 | $31.39 | $31.45 | 1.67M |
| Oct 27, 2026 | $31.40 | $32.11 | $31.1782 | $31.68 | 2.22M |
| Oct 26, 2026 | $31.41 | $32.26 | $31.35 | $31.81 | 1.55M |
| Oct 23, 2026 | $32.13 | $32.13 | $30.91 | $31.20 | 1.89M |
| Oct 22, 2026 | $31.68 | $32.50 | $31.35 | $32.20 | 2.08M |
| Oct 21, 2026 | $32.645 | $32.94 | $31.65 | $31.87 | 1.69M |
| Oct 20, 2026 | $31.89 | $33.30 | $31.75 | $32.82 | 4.49M |
| Oct 19, 2026 | $29.41 | $33.01 | $28.99 | $31.89 | 5.8M |
| Oct 16, 2026 | $29.18 | $29.37 | $28.15 | $28.82 | 1.8M |
| Oct 15, 2026 | $26.93 | $29.46 | $26.93 | $29.10 | 3.96M |
The latest Smart Investors Daily articles mentioning ARQT.
Company
Market Activity
Research & News


ARQT research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
3 matching articles.
SeekingAlpha · Nov 9, 2026
2026-11-09. The following slide deck was published by Arcutis Biotherapeutics, Inc.
Yahoo · Nov 7, 2026
Arcutis Biotherapeutics Inc (ARQT) posted strong Q3 2026 net product revenue growth, lifted full-year guidance to $535-$545 million, and outlined multiple pipeline catalysts despite elevated expenses.
Yahoo · Nov 6, 2026
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units (RSUs) of Arcutis common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of
The latest Smart Investors Daily articles mentioning ARQT.